What China SXT Pharmaceuticals, Inc. does

China SXT Pharmaceuticals, Inc. is a specialty pharmaceutical company founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China. The company develops, manufactures, and sells Traditional Chinese Medicine Pieces (TCMPs) across five product categories: Directly-Oral TCMPs, After-Soaking-Oral TCMPs, Fine TCMPs, Regular TCMPs, and TCM Homologous Supplements (TCMHS). Its portfolio includes approximately 430 regular TCMP products listed on the China Pharmacopoeia, over 15 fine TCMP products manufactured manually from authentic regional ingredients, 9 Directly-Oral TCMP products, and 9 After-Soaking-Oral TCMP products. The company became the first manufacturer nationwide in China to pass GMP compliance inspection for lyophilization (freeze-drying) processing, which it uses for advanced Directly-Oral products such as Luxuejin, Kuihuapan, and Zhudanfen. The company was the first Taizhou TCMP manufacturer listed on NASDAQ, trading under ticker SXTC since January 2019 after an IPO at $4.00 per share.

The company operates a sales-led B2B distribution model, selling directly to hospitals and drug stores across ten provinces in China. Revenue is generated through one-time institutional sales with no disclosed pricing transparency. For the six months ended September 30, 2020, total revenue was $3.86 million (a 20% increase year-over-year) with a gross margin of 73.1%, operating income of $1.16 million, and net income of $1.38 million. Revenue mix was Advanced TCMP 44%, TCMHS 29%, Regular TCMP 21%, and Fine TCMP 6%. By 2025 annual revenue had contracted to approximately $1.74 million per third-party comparison data, and the company has undertaken multiple dilutive financings (including a $7.2M private placement in 2020, $3.5M and $4.1M offerings in January 2022, and a $10M registered direct offering in January 2026) at progressively lower share prices, alongside a 1-for-150 reverse stock split and a dual-class share structure reclassification to address NASDAQ listing compliance. In January 2026 the company announced a Strategic AI Insights Initiative intended to incorporate AI-driven analytics into product portfolio and market intelligence processes.

Name

China SXT Pharmaceuticals, Inc.

Legal name

China SXT Pharmaceuticals, Inc.

Website

https://sxtchina.com

Company type

Public

Founded year

2005

Operating status

Operating

Headcount range

51–100 employees

Short description

China SXT Pharmaceuticals is a NASDAQ-listed Chinese specialty pharmaceutical company (SXTC) that manufactures and sells Traditional Chinese Medicine Pieces — including lyophilized Directly-Oral and After-Soaking-Oral TCMPs — to hospitals and drug stores across ten provinces in China.

Ownership category

akta.pro rank

Product category

Traditional Chinese Medicine Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

akta.pro primary industry

Lyophilization (Freeze-Drying) CDMO (HLAGABAI)

Keywords

• Traditional chinese medicine
• Pharmaceutical manufacturing
• TCMP products
• Lyophilization processing
• Health supplements

Headquarters

HQ city

Taizhou

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Traditional Chinese Medicine Pieces (TCMP) Sales: The company generates revenue primarily from the manufacture and sales of four types of traditional Chinese medicine pieces: Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), Fine TCMPs, Regular TCMPs, and TCM Homologous Supplements (TCMHS). Revenue is generated through B2B sales to hospitals and drug stores. For the six months ended September 30, 2020, total revenue was $3,860,501 with a gross margin of 73.1%.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

China SXT Pharmaceuticals develops, manufactures, and sells Traditional Chinese Medicine Pieces (TCMPs), including Advanced TCMPs (Directly-Oral and After-Soaking-Oral), Fine TCMPs, Regular TCMPs, and TCM Homologous Supplements (TCMHS). The company sells its products primarily to hospitals and drug stores across ten provinces in China, and operates the first GMP-compliant lyophilization (freeze-drying) production facility for Directly-Oral TCMPs in the country.

Product overview

China SXT Pharmaceuticals is a specialty pharmaceutical company that develops, manufactures, and sells Traditional Chinese Medicine Pieces (TCMPs). The product portfolio consists of five main categories: (1) Directly-Oral TCMP - advanced products that can be taken orally without decoction; (2) After-Soaking-Oral TCMP - products that can be brewed in boiling water like tea; (3) Fine TCMP - over 30 manually manufactured products from high-quality authentic regional ingredients; (4) Regular TCMP - nearly 600 products listed on China Pharmacopoeia; and (5) TCM Homologous Supplements (TCMHS) - health-supporting food products including solid beverages. The company also operates a GMP-certified lyophilization (freeze-drying) production facility, being the first in China to achieve this certification for Directly-Oral TCMP manufacturing. Key products include LuXueJing (Luxuejin), Kuihuapan, and Zhudanfen Advanced TCMP products.

Differentiator

Problem solved

Functional benefit

Products and services

• Directly-Oral TCMP Novel advanced Traditional Chinese Medicine Pieces defined on Pharmaceutical GMP and China Pharmacopoeia that can be taken orally without decocting. Products comply with CFDA regulations while keeping principles of TCM. Advantages include non-decocting, keeping original ingredients, improving bioavailability, easy storage, and enhanced safety. The company produces 9 Directly-Oral TCMP products.
• After-Soaking-Oral TCMP New type of advanced Traditional Chinese Medicine Pieces which can be taken after soaking with hot water (not decocting), as defined on China Pharmacopoeia version 2015 Part IV. Products comply with CFDA regulations with advantages in non-decocting, keeping original ingredients, improving bioavailability, easy storage, and safety. The company produces 9 After-Soaking-Oral TCMP products.
• Fine TCMP Over 30 fine Traditional Chinese Medicine Pieces products manufactured manually from high-quality authentic ingredients derived from their region of origin. Products include LuRong, YanWo, YeShanSen, DangGui, DongChongXiaCao, GouQiZi, HuangQi, JinYinHua, and others. Target market includes drug stores and hospitals.
• Regular TCMP Near 600 regular Traditional Chinese Medicine Pieces listed on China Pharmacopoeia version 2015 Part I for hospitals and drug stores for treatment of various diseases or healthy purposes. Contains multiple specifications. Revenue from regular TCMP accounted for 21% of total revenue for the six months ended September 30, 2020.
• TCM Homologous Supplements (TCMHS) Classification of health-supporting food used traditionally in China as TCM but also consumed as food. Includes four solid beverage products developed and commercially launched in April 2019. Revenue from TCMHS accounted for 29% of total revenue for the six months ended September 30, 2020.
• LuXueJing (Luxuejin) Directly-Oral TCMP Directly-Oral TCMP product made from fresh bloods of Cervus nippon or Cervus elaphus. Indicated for leukopenia, thrombocytopenia, hypoimmunity, chronic anemia, aplastic anemia, erectile dysfunction, and postoperative rehabilitation. Produced using lyophilization (freeze-drying) process for which the company became the first manufacturer nationwide in China to pass GMP compliance inspection.
• Kuihuapan After-Soaking-Oral TCMP After-Soaking-Oral TCMP product produced according to Chinese Pharmacopoeia 2020 Edition specifications. Has functions of clearing heat, calming liver, dredging collaterals and relieving pain. Indicated for dizziness, tinnitus, joint pain, hyperuricemia, gout, hypertension. Expected annual output of 300,000 bottles.
• Zhudanfen Directly-Oral TCMP Directly-Oral TCMP produced according to Chinese Pharmacopoeia 2020 Edition. Has functions of clearing heat and moistening dryness, relieving cough and asthma, and detoxifying. Indicated for cough, asthma, fever, thirst, red eyes, throat obstruction, jaundice, diarrhea, dysentery, constipation, sores. Listed in National Medical Insurance Catalogue.
• XueJie (Dry Fruit Resins Powders) Directly-Oral TCMP Dry fruit resins of Daemonorops draco Bl. Brick red powders indicated for myocardial infarction, coronary heart disease, angina pectoris, anorectal and gastrointestinal diseases, internal and external bleeding, chronic inflammatory colitis, diabetic foot ulcer.
• HuangShuKuiHua (Dry Corollas Powders) Directly-Oral TCMP Dry corollas of Abelmoschus manihot. Yellowish to isabellinus powders indicated for chronic nephritis, hydremic nephritis, adiabatic nephropathy, oral ulcers, parotitis, edemas, cerebrovascular disease, cancer.

Quantifiable outcome

• 20% revenue increase to $3.86 million for the six months ended September 30, 2020 compared to the prior year period
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Partnerships

Eleven partnerships are on record, tiered minor.

• Hunter Taubman Fischer & Li LLCminorOthers · 2 January 2019Hunter Taubman Fischer & Li LLC acted as U.S. legal counsel to the company for the IPO. Listed as a business partner on the company's website.
• Sichenzia Ross Ference LLPminorOthers · 2 January 2019Sichenzia Ross Ference LLP acted as legal counsel to the underwriter for the IPO.
• Agricultural Bank of ChinaminorOthersListed as a business partner on the company website. The company maintains banking relationships with major Chinese financial institutions.
• China Merchants BankminorOthersListed as a business partner on the company website. Banking services partner.
• China Construction BankminorOthersListed as a business partner on the company website. Banking services partner.
• Bank of ChinaminorOthersListed as a business partner on the company website. Banking services partner.
• Zhejiang Merchants BankminorOthersListed as a business partner on the company website. Banking services partner.
• Bank of CommunicationsminorOthersListed as a business partner on the company website. Banking services partner.
• Bank of JiangsuminorOthersListed as a business partner on the company website. Banking services partner.
• Jiangsu Changjiang Commercial BankminorOthersListed as a business partner on the company website. The company has financial guarantee agreements with Jiangsu Changjiang Commercial Bank for related party borrowings.
• ZH CPA, LLCminorOthersListed as a business partner on the company website. Accounting and audit services partner.

Scale indicators13 records

Recent moves9 records

Expansion highlights5 records

Broad incumbents

• Yiling Pharmaceutical Co., Ltd. Innovative TCM pharmaceutical company focused on cardiovascular, respiratory, and oncology indications. Comparable to China SXT in TCM innovation focus and Chinese institutional sales motion, though at significantly larger scale and with a more diversified therapeutic portfolio.
• Kangmei Pharmaceutical Co., Ltd. Chinese TCM pharmaceutical company focused on Chinese herbal medicines, TCM finished products, and pharmaceutical distribution. Comparable to China SXT in TCM product focus and Chinese distribution model, though significantly larger and broader in scope, and a more vertically integrated value chain.
• China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Major Chinese TCM and OTC pharmaceutical manufacturer under the China Resources umbrella. Overlaps with China SXT in Chinese herbal medicines and OTC retail distribution, but operates at vastly larger scale with national reach and a recognized consumer brand.
• Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited: Major state-owned Chinese pharmaceutical group with significant TCM operations including herbal pieces, finished TCM products, and Chinese patent medicines. Comparable to China SXT in TCM finished products category but far broader and larger in scale.
• Shanghai Pharmaceuticals Holding Co., Ltd. One of China's largest pharmaceutical groups with operations spanning R&D, manufacturing, and distribution of both chemical drugs and TCM products. Overlaps with China SXT in Chinese pharmaceutical distribution and TCM segments, but operates at vastly larger scale with national distribution infrastructure.
• Yunnan Baiyao Group Co., Ltd. Major Chinese TCM conglomerate with a diversified portfolio spanning TCM finished products, pharmaceuticals, and health products. Operates in overlapping categories (TCM finished products, Chinese herbal preparations) but at vastly larger scale and broader therapeutic reach than China SXT.
• Beijing Tongrentang Co., Ltd. Historic Chinese TCM manufacturer with a flagship brand in traditional Chinese medicine products. Overlaps with China SXT in TCM finished products and Chinese institutional/retail distribution channels, but operates at vastly larger scale with a much broader product portfolio and national brand recognition.

Direct peers

• China Shineway Pharmaceutical Holdings Limited: Hong Kong-listed TCM manufacturer focused on Chinese medicine injections, granules, and finished dosage forms. Comparable to China SXT in TCM product focus, Chinese institutional distribution model, and mid-cap scale.
• China Traditional Chinese Medicine Holdings Limited: Hong Kong-listed leader in TCM granules and Traditional Chinese Medicine Pieces, producing products that directly overlap with China SXT's TCMP portfolio. Comparable in core product category and Chinese institutional/cross-border go-to-market motion, though substantially larger in scale and more established in the National Reimbursement Drug List.

Emerging players

• Hutchison China MediTech Limited (Hutchmed): NASDAQ- and HKEX-listed innovative Chinese pharmaceutical company with TCM heritage and modern drug development. Comparable to China SXT as a NASDAQ-listed Chinese pharma with an innovative pipeline focus, though operating in different therapeutic areas (primarily oncology) and at a meaningfully larger scale.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/china-sxt-pharmaceuticals-inc

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about China SXT Pharmaceuticals, Inc.